AbCellera Biologics Inc.

NASDAQ:ABCL

Biotechnology

Healthcare
$10.47 -0.28%

-$0.02 today

Market cap
$3.42B
Beta
1.20
P/E (TTM)
-11.4
EPS (TTM)
-$0.47
52W Low $2.75High $6.79

Volume 2.48M

Average 6.37M

Returns on capital

AbCellera Biologics Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-15.1%

avg -2.5%

ROIC

-13.8%

avg -5.0%

ROA

-10.8%

avg -0.9%

Analysis

ROA is currently the strongest return metric at -10.8% versus its period average of -0.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Carl Hansen

Chief Executive Officer, President & ChairpersonUSD 931.15K51——

Andrew Booth

Chief Financial OfficerUSD 726.81K52491.40K0.16%

Tryn T. Stimart

Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy OfficerUSD 709.28K56——

Veronique Lecault

Chief Technology Officer & DirectorUSD 681.65K415.20M1.70%

Caitlin Webster CIPD

Director of Talent Development————

Marcie Thiessen

Senior Director of Finance & Accounting————

Adam Clarke

Senior Vice President of Discovery————

Andrew Knowles

Vice President of Operations————

Martin Hogan

Senior Director of Strategic Finance & IR————

Murray McCutcheon

Senior Vice President of Partnering————

Tiffany Chiu

Vice President of Communications————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 13, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

11

$3.47M

Sells

0

$0.00

Net Transaction Value

+$3.47M

Net buying

Most Active

Booth Andrew

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 13, 26

Booth Andrew

Direct

Buy$97.4K
Nov 12, 26

Thermopylae Holdings Ltd.

Direct

Buy$698.9K
Aug 24, 26

Hayden Michael R

Indirect

Buy$570.4K
Aug 18, 26

Montalbano John S.

Direct

Buy$110.3K
Aug 14, 26

Booth Andrew

Direct

Buy$383.9K
Aug 12, 26

Hayden Michael R

Indirect

Buy$481K
May 14, 26

Montalbano John S.

Direct

Buy$95.4K
Feb 27, 26

Thermopylae Holdings Ltd.

Direct

Buy$130.7K
Feb 27, 26

Booth Andrew

Direct

Buy$145.7K
Feb 26, 26

Thermopylae Holdings Ltd.

Direct

Buy$580.3K

1–10 of 11

Summary

Insiders reported 11 buys worth $3.47M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $3.47M. Booth Andrew was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/A-46.3%
+10.6% (5yr)6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Recent growth has been strongest in Revenue at -46.3% over three years. Forward estimates point to Revenue at +10.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does AbCellera Biologics Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ABCL's management, answered from reported figures.

Who manages ABCL?

AbCellera Biologics Inc. (ABCL) lists 11 active executives. The top listed executive is Caitlin Webster CIPD, Director of Talent Development.

Are ABCL insiders buying or selling?

Recent insider activity shows net selling of $132.80M.